MedTrace Logo

Patient Reported Outcome Measures (PROMs) With Trabectedin

NCT03959033 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2022-08-31

No results posted yet for this study

Summary

Patient reported outcome measures (PROMs) are central to understanding the impact of cancer treatments on patients. Treatment may control cancer growth, and even sometimes modestly improve the length of life, but at the expense of disruption of lifestyle, and of toxicities. It is very important to use PROMs to evaluate the balance between these risks and benefits to understand the overall impact of the treatment.

It remains poorly described whether patients report improved outcomes during palliative chemotherapy with trabectedin, using high quality questionnaires, and how this may vary with the clinical effects and duration of the treatment and characteristics of the patient.

Conditions

  • Sarcoma
  • Liposarcoma
  • Leiomyosarcoma

Sponsors & Collaborators

  • University of Leeds

    lead OTHER

Principal Investigators

Eligibility

Min Age
16 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-29
Primary Completion
2019-08-28
Completion
2019-08-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03959033 on ClinicalTrials.gov